Recurrence

Blue Earth Diagnostics Announces Results of an Analysis of the Impact of Axumin® (Fluciclovine F 18) PET/CT Imaging on Androgen Deprivation Therapy (ADT) Planning in Recurrent Prostate Cancer

Monday, September 27, 2021 - 1:30pm

This analysis characterized the impact of Axumin PET/CT on sites of disease recurrence and plans for androgen deprivation therapy (ADT) in patients with biochemical recurrence of prostate cancer.

Key Points: 
  • This analysis characterized the impact of Axumin PET/CT on sites of disease recurrence and plans for androgen deprivation therapy (ADT) in patients with biochemical recurrence of prostate cancer.
  • Of 60 patients originally planned for ADT monotherapy, only 25% (15) were still due to receive ADT monotherapy after Axumin PET/CT imaging.
  • Axumin, a novel amino acid-based radiopharmaceutical, is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
  • Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

The Worldwide Laboratory Developed Test Industry is Expected to Reach $7+ Billion by 2028 - ResearchAndMarkets.com

Monday, September 27, 2021 - 12:00pm

Laboratory developed tests (LDTs) are designed for the early and precise diagnosis of diseases and monitoring the progress of patient treatment.

Key Points: 
  • Laboratory developed tests (LDTs) are designed for the early and precise diagnosis of diseases and monitoring the progress of patient treatment.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Laboratory Developed Test Market.
  • The key findings and recommendations highlight crucial progressive industry trends in the Laboratory Developed Test, thereby allowing players across the value chain to develop effective long-term strategies.
  • 5.2 Global Laboratory Developed Test Market, By Geography - Forecast and Analysis
    9.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
    9.5 South & Central America: Impact Assessment of COVID-19 Pandemic

Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference

Monday, September 27, 2021 - 11:00am

The Benzinga Healthcare Small Cap Conference connects small cap companies, investors, and traders.

Key Points: 
  • The Benzinga Healthcare Small Cap Conference connects small cap companies, investors, and traders.
  • Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

Treace Announces New ALIGN3D™ Data at the 2021 AOFAS Annual Meeting

Thursday, September 23, 2021 - 9:15pm

Updated interim analysis from the ALIGN3D clinical study demonstrated positive radiographic and patient-reported outcomes starting at 6 weeks and maintained at 24 months following the Lapiplasty procedure.

Key Points: 
  • Updated interim analysis from the ALIGN3D clinical study demonstrated positive radiographic and patient-reported outcomes starting at 6 weeks and maintained at 24 months following the Lapiplasty procedure.
  • John T. Treace, CEO of Treace commented, New data continues to demonstrate sustained successful procedural and patient outcomes from our proprietary Lapiplasty System, specifically designed to address the unmet needs of bunion patients.
  • A poster summarizing the data and conclusions can be accessed by meeting attendees through the AOFAS mobile app.
  • The AOFAS Annual Meeting is the premier event for foot and ankle education, offering presentations from renowned speakers, special interest forums, social events, and the latest products and technology.

IceCure Medical Reports Financial Results for the First Half of 2021 and Recent Operating Highlights

Thursday, September 23, 2021 - 10:00pm

o Asian distribution partnership with Terumo Corporation (Tokyo: 4543, TRUMY:OTC US) expanded to include Thailand, in addition to Japan and Singapore.

Key Points: 
  • o Asian distribution partnership with Terumo Corporation (Tokyo: 4543, TRUMY:OTC US) expanded to include Thailand, in addition to Japan and Singapore.
  • The Company's ordinary shares commenced trading on the Nasdaq Capital Market on August 26, 2021.
  • "I am excited by our team's growing list of accomplishments throughout the business thus far in 2021.
  • Total operating expenses for the six months ended June 30, 2021 were approximately $4.9 million.

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

Thursday, September 23, 2021 - 1:30pm

This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.

Key Points: 
  • This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.
  • The data included in the case study are based on earlier Phase 1 results and compassionate use of AL101 in desmoid tumors.
  • Both of these patients case studies represent additional evidence to support the development of our gamma secretase inhibitor, AL102 for the treatment of desmoid tumors.
  • The body of data conducted by BMS in patients with desmoid tumors implicating the role of gamma secretase inhibition furthers our hypothesis for treating desmoid tumors through AL102s mechanism of action, said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala.

TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

Thursday, September 23, 2021 - 12:30pm

The key results of the study demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions.

Key Points: 
  • The key results of the study demonstrated that TTX-MC138, when injected intravenously, accumulated in metastatic lesions.
  • These results suggest that TransCodes TTX platform delivers its therapeutic candidate as intended and the company believes supports clinical evaluation of TTX-MC138.
  • Our preclinical data further suggest the therapeutic potential of TTX-MC138, and we look forward to our Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.
  • The Companys lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide.

Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference

Thursday, September 23, 2021 - 11:00am

CEO Snehal Patel will make a virtual presentation on Wednesday, September 29, 2021 at 2:00 pm ET to conference attendees.

Key Points: 
  • CEO Snehal Patel will make a virtual presentation on Wednesday, September 29, 2021 at 2:00 pm ET to conference attendees.
  • The 6th Annual Cantor Global Healthcare Conference will include leading industry speakers and more than 300 presenting companies, one-on-one meetings, and panel discussions.
  • Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
  • For more information on Greenwich LifeSciences, please visit the Companys website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS .

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

Wednesday, September 22, 2021 - 1:00pm

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced plans to present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021.
  • These findings support previous Boundless Bio published work that ecDNA is an important underlying cause of cancer resistance and reinforces the critical need for novel therapeutic strategies to address ecDNA enabled cancers.
  • ecDNA replicate within cancer cells and can be passed to daughter cells asymmetrically during cell division, thereby constituting a primary driver of focal gene amplification and copy number heterogeneity in cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

New 4th Category of Hernia Mesh Can Drastically Reduce Post-Operative Chronic Pain and Recurrence

Tuesday, September 21, 2021 - 5:06pm

Surgeons are beginning to recognize the interactions of specific meshes within the patient and their relationship to outcomes.

Key Points: 
  • Surgeons are beginning to recognize the interactions of specific meshes within the patient and their relationship to outcomes.
  • In this pilot study, we found varying degrees of fat attachment to knitted and woven hernia mesh, which might inhibit fibrous connective tissue ingrowth.
  • New designs for hernia mesh can be implemented that reduces adipose tissue attachment while promoting fibrous connective tissue ingrowth.
  • SURGIMESH is a proprietary 21st century alternative to the use of older knitted or woven meshes and has the potential to significantly reduce chronic pain and recurrence.